Alessandro Pallamolla, CEO of Contatti Medical, said: “Contatti is a well-established company located in southern Brazil, with more than 36 years of experience in providing the right answers to the health care market. We couldn’t be happier to be with CytoSorbents and leveraged our strengths in heart surgery, organ transplantation and blood bank control to contribute to CytoSorb’s success. CytoSorb is a state-of-the-art treatment for intensive care and cardiac surgery, with massive prospective in Brazil, given the highest incidence of central disease and sepsis in Brazil. In addition, the early availability of CytoSorb comes at a very delicate time from the COVID-19 crisis in Brazil. We look forward to this opportunity to paint with CytoSorbents and explore all the odds in our country together. “
Dr. Phillip Chan, CEO of CytoSorbents said: “We are pleased to announce the official registration of CytoSorb in Brazil and the launch of our partnership with Contatti Medical to distribute CytoSorb in the country. We are very pleased to collaborate with Contatti, whose advertising objective is parallel to ours, with a vast network within hospitals and among doctors in Brazil, our immediate goal will be to help treat patients with potentially fatal headaches of COVID-19 infection, with 30,000 to 40,000 new cases of coronavirus compatible with the day , and a total of 4. 5 million cases in the country to date, the third only in the United States and India. “